Abo Bibliothek: Guest
Critical Reviews™ in Oncogenesis

Erscheint 4 Ausgaben pro Jahr

ISSN Druckformat: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Cancer Genetics/Epigenetics and the X Chromosome: Possible New Links for Malignant Glioma Pathogenesis and Immune-Based Therapies

Volumen 11, Ausgabe 1, 2000, 19 pages
DOI: 10.1615/CritRevOncog.v11.i1.40
Get accessGet access

ABSTRAKT

Human high-grade gliomas (HGGs) are rapidly progressing heterogeneous brain tumors of unknown etiology and there are no effective treatment modalities available. The recent discovery of cancer-specific antigens has opened new doors for specific tumor-targeted treatments using passive and active immunotherapeutic strategies. In particular, SEREX (serological analysis of recombinant cDNA expression libraries) has aided in the discovery of numerous new tumor antigens. These specific tumor antigens are located on chromosome X and are expressed predominantly in the testes among normal organs, and hence termed Cancer/Testis Antigens (CTAs). We found that the vast majority of HGG patients overexpress a receptor for an immune regulatory cytokine, interleukin 13 (IL-13), which differs from the normal tissue physiological receptor. Interestingly, the HGG-associated receptor protein, IL-13Rα, is expressed solely in the testes and its gene is localized to chromosome X, which mirror the expression pattern and genomic localization of CTAs. There is little evidence for frequent gross structural abnormalities on chromosome X in HGG. Although the mechanism that causes X chromosome-linked CTAs to be aberrantly expressed in tumors is not fully understood, evidence is beginning to point toward the DNA methylation dysregulation that occurs in tumor cells as being implicit in this process and perhaps in the oncogenic process as well. Therefore, further study of the phenomenon of CTAs may bring the dual benefit of better understanding tumorigenesis and providing new molecular tools for better management of HGGs. Also, we propose that the X chromosome may in fact be an important player in HGG oncogenesis.

REFERENZIERT VON
  1. POWERS ROBERT, SIEGEL MARSHALL M., APPLICATIONS OF NUCLEAR MAGNETIC RESONANCE AND MASS SPECTROMETRY TO ANTICANCER DRUG DISCOVERY, in Novel Anticancer Agents, 2006. Crossref

  2. Hari Babu Lingaiah, Perumal Srinivasan, Balasubramanian Maruthaiveeran Periyasamy, Myrtenal attenuates diethylnitrosamine-induced hepatocellular carcinoma in rats by stabilizing intrinsic antioxidants and modulating apoptotic and anti-apoptotic cascades, Cellular Oncology, 35, 4, 2012. Crossref

  3. Rajesh Venugopalan, Perumal Perumal, Chemopreventive and antioxidant activity by Smilax zeylanica leaf extract against N-nitrosodiethylamine induced hepatocarcinogenesis in wistar albino rats, Oriental Pharmacy and Experimental Medicine, 14, 2, 2014. Crossref

  4. Yokokawa Junko, Bera Tapan K., Palena Claudia, Cereda Vittore, Remondo Cinzia, Gulley James L., Arlen Philip M., Pastan Ira, Schlom Jeffrey, Tsang Kwong Y., Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4), International Journal of Cancer, 121, 3, 2007. Crossref

  5. Dai Xue-jun, Jiang Wei-jian, Wang Wei-min, Zhao Shu-jin, Drug or Vaccine?, Drugs, 70, 12, 2010. Crossref

  6. Szabó Erzsébet, Páska Csilla, Novák Pál Kaposi, Schaff Zsuzsa, Kiss András, Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis, Pathology & Oncology Research, 10, 1, 2004. Crossref

  7. Debinski Waldemar, Molecular targeting with recombinant cytotoxins for the treatment of brain tumors, Drug Development Research, 69, 7, 2008. Crossref

  8. DUNN BARBARA K., VERMA MUKESH, UMAR ASAD, Epigenetics in Cancer Prevention: Early Detection and Risk Assessment, Annals of the New York Academy of Sciences, 983, 1, 2003. Crossref

  9. DEBINSKI WALDEMAR, GIBO DENISE, MINTZ AKIVA, Epigenetics in High-Grade Astrocytomas, Annals of the New York Academy of Sciences, 983, 1, 2003. Crossref

  10. Bollos Rubens H., Nakamura Mary U., Lapchick Valderez B. V., Bevilacqua Estela M. A. F., Correa Mariangela, Daher Silvia, Ishigai Márcia M. S., Jasiulionis Miriam G., Metastatic melanoma positively influences pregnancy outcome in a mouse model: could a deadly tumor support embryo life?, Clinical & Experimental Metastasis, 25, 1, 2008. Crossref

  11. Mintz Akiva, Gibo Denise M., MadhanKumar A.B., Cladel Nancy M., Christensen Neil D., Debinski Waldemar, Protein- and DNA-Based Active Immunotherapy Targeting Interleukin-13 Receptor Alpha2, Cancer Biotherapy and Radiopharmaceuticals, 23, 5, 2008. Crossref

  12. Verma Mukesh, Srivastava Sudhir, Epigenetics in cancer: implications for early detection and prevention, The Lancet Oncology, 3, 12, 2002. Crossref

  13. Eisenmesser Elan Zohar, Horita David A, Altieri Amanda S, Byrd R.Andrew, Solution structure of interleukin-13 and insights into receptor engagement11Edited by P. E. Wright, Journal of Molecular Biology, 310, 1, 2001. Crossref

  14. Debinski Waldemar, Local Treatment of Brain Tumors with Targeted Chimera Cytotoxic Proteins, Cancer Investigation, 20, 5-6, 2002. Crossref

  15. Virasch Nisha, Kruse Carol A., STRATEGIES USING THE IMMUNE SYSTEM FOR THERAPY OF BRAIN TUMORS, Hematology/Oncology Clinics of North America, 15, 6, 2001. Crossref

  16. Mitchell Duane A., Sampson John H., Toward effective immunotherapy for the treatment of malignant brain tumors, Neurotherapeutics, 6, 3, 2009. Crossref

  17. Nash Kevin T., Thompson Jeffrey P., Debinski Waldemar, Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins, Critical Reviews in Oncology/Hematology, 39, 1-2, 2001. Crossref

  18. Rhomberg Lorenz R., Baetcke Karl, Blancato Jerry, Bus James, Cohen Samuel, Conolly Rory, Dixit Rakesh, Doe John, Ekelman Karen, Fenner-Crisp Penny, Harvey Paul, Hattis Dale, Jacobs Abigail, Jacobson-Kram David, Lewandowski Tom, Liteplo Robert, Pelkonen Olavi, Rice Jerry, Somers Diana, Turturro Angelo, West Webster, Olin Stephen, Issues in the Design and Interpretation of Chronic Toxicity and Carcinogenicity Studies in Rodents: Approaches to Dose Selection, Critical Reviews in Toxicology, 37, 9, 2007. Crossref

  19. Verma Mukesh, Maruvada Padma, Srivastava Sudhir, Epigenetics and Cancer, Critical Reviews in Clinical Laboratory Sciences, 41, 5-6, 2004. Crossref

  20. Zhang Zhan, Wang Di, Qiao Shanlei, Wu Xinyue, Cao Shuyuan, Wang Li, Su Xiaojian, Li Lei, Metabolic and microbial signatures in rat hepatocellular carcinoma treated with caffeic acid and chlorogenic acid, Scientific Reports, 7, 1, 2017. Crossref

  21. Feo Francesco, Frau Maddalena, Tomasi Maria L., Brozzetti Stefania, Pascale Rosa M., Genetic and Epigenetic Control of Molecular Alterations in Hepatocellular Carcinoma, Experimental Biology and Medicine, 234, 7, 2009. Crossref

  22. Debinski Waldemar, Dickinson Peter, Rossmeisl John H., Robertson John, Gibo Denise M., Lesniak Maciej S., New Agents for Targeting of IL-13RA2 Expressed in Primary Human and Canine Brain Tumors, PLoS ONE, 8, 10, 2013. Crossref

  23. Debinski Waldemar, Gibo Denise M., Molecular Expression Analysis of Restrictive Receptor for Interleukin 13, a Brain Tumor-associated Cancer/Testis Antigen, Molecular Medicine, 6, 5, 2000. Crossref

  24. Zendman Albert J.W., Ruiter Dirk J., Van Muijen Goos N.P., Cancer/testis-associated genes: Identification, expression profile, and putative function, Journal of Cellular Physiology, 194, 3, 2003. Crossref

  25. Debinski Waldemar, Slagle-Webb Becky, Achen Marc G., Stacker Steven A., Tulchinsky Eugene, Gillespie G. Yancey, Gibo Denise M., VEGF-D is an X-linked/AP-1 Regulated Putative Onco-angiogen in Human Glioblastoma Multiforme, Molecular Medicine, 7, 9, 2001. Crossref

  26. Calvisi Diego F., Factor Valentina M., Thorgeirsson Snorri S., Transgenic and Knockout Mouse Models of Liver Cancer, in Molecular Genetics of Liver Neoplasia, 2010. Crossref

  27. Huang Yu-Chuen, Shih Yi-Ping, Li Chun-Chih, Liao Li-Ying, Chen Yi-Ming A., Characterization of Genetic Polymorphism of Glycine N-Methyltransferase Gene in Hepatocellular Carcinoma, in Hormonal Carcinogenesis IV, 2005. Crossref

  28. Shimato Shinji, Maier Lisa M, Maier Richard, Bruce Jeffrey N, Anderson Richard CE, Anderson David E, Profound tumor-specific Th2 bias in patients with malignant glioma, BMC Cancer, 12, 1, 2012. Crossref

  29. Grizzi Fabio, Gaetani Paolo, Franceschini Barbara, Di Ieva Antonio, Colombo Piergiuseppe, Ceva-Grimaldi Giorgia, Bollati Angelo, Frezza Eldo E, Cobos E, Baena Riccardo Rodriguez y, Dioguardi Nicola, Chiriva-Internati Maurizio, Sperm protein 17 is expressed in human nervous system tumours, BMC Cancer, 6, 1, 2006. Crossref

  30. Debinski Waldemar, Gibo Denise M., Fos-Related Antigen 1 Modulates Malignant Features of Glioma Cells, Molecular Cancer Research, 3, 4, 2005. Crossref

  31. Koslowski Michael, Bell Carolin, Seitz Gerhard, Lehr Hans-Anton, Roemer Klaus, Müntefering Horst, Huber Christoph, Sahin Ugur, Türeci Özlem, Frequent Nonrandom Activation of Germ-Line Genes in Human Cancer, Cancer Research, 64, 17, 2004. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain